Table 1.
Patient characteristics and transplant-related parameters.
| Variables | PTCy-ATG group (N = 53) | ATG group (N = 51) | P values |
|---|---|---|---|
| Median age in years (range) | 29 (2–59) | 29 (4–52) | 0.969 |
| Recipient sex | 0.219 | ||
| Male | 28 (52.8%) | 33 (64.7%) | |
| Female | 25 (47.2%) | 18 (35.3%) | |
| Disease type | 0.362 | ||
| Acute myeloid leukemia (AML) | 24 (45.3%) | 31 (60.8%) | |
| Acute lymphoblastic leukemia (ALL) | 22 (41.5%) | 16 (31.4%) | |
| Myelodysplastic syndromes (MDS) | 6 (11.3%) | 4 (7.8%) | |
| CMML | 1 (1.9%) | 0 | |
| HCT-CI | 0.843 | ||
| ≥3 | 8 (15.1%) | 7 (13.7%) | |
| <3 | 45 (84.9%) | 44 (86.3%) | |
| Disease risk index | 0.230 | ||
| Low/intermediate | 26 (49.1%) | 31 (60.8%) | |
| High/very high | 27 (50.9%) | 20 (39.2%) | |
| Minimal residual disease at transplant | 0.708 | ||
| Negative | 30 (56.6%) | 27 (52.9%) | |
| Positive | 23 (43.4%) | 24 (47.1%) | |
| KPS | 0.563 | ||
| <90 | 14 (26.4%) | 11 (21.6%) | |
| ≥90 | 39 (73.6%) | 40 (78.4%) | |
| Donor sex | 0.335 | ||
| Male | 48 (90.6%) | 43 (84.3%) | |
| Female | 5 (9.4%) | 8 (15.7%) | |
| Donor age (year, median, range) | 30 (21-48) | 31 (18-46) | 0.862 |
| Donor-recipient pair | 0.513 | ||
| Female to female | 2 | 2 | |
| Female to male | 3 | 6 | |
| Male to female | 23 | 16 | |
| Male to male | 25 | 27 | |
| Blood type matching | 0.723 | ||
| Match | 19 (35.8%) | 20 (39.2%) | |
| Mismatch | 34 (64.2%) | 31 (60.8%) | |
| Median mononuclear cell (range, 108/kg) | 11.07 (1.11–25.95) | 11.12 (4.43–29.30) | 0.592 |
| Median CD34 + cells (range, 106/kg) | 6.57 (0.16–18.69) | 6.4 (1.75–35.7) | 0.709 |
| Median follow-up for survivors (range, days) | 561 (182–1450) | 600 (196–1370) | 0.196 |
PTCy post-transplant cyclophosphamide, ATG anti-thymocyte globulin, AML acute myelocytic leukemia, ALL acute lymphocyte leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, HCT-CI hematopoietic cell transplantation-comorbidity index, KPS Kanofsky performance score.